Phase I and Pharmacokinetic Study of Oral UFT, a Combination of the 5-Fluorouracil Prodrug Tegafur and Uracil

Clinical Cancer Research

Volumn 2, Issue 9, 1996, Pages 1461-1467

  Muggia, Franco M ^a   Wu, Xiaoyang ^a   Spicer, Darcy ^a   Groshen, Susan ^a   Jeffers, Susan ^a   Leichman, C Gail ^a   Leichman, Lawrence ^a   Chan, Kenneth K ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; PRODRUG; TEGAFUR; UFT(R) DRUG; URACIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; FATIGUE; FEMALE; HUMAN; MALE; MIDDLE AGED; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; COHORT STUDIES; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FATIGUE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NAUSEA; PRODRUGS; TEGAFUR; URACIL; VOMITING;

EID: 0030223052     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Hiller, S. A., Lidaks, M. Y., Zhuk, R. A., Pets, K. I., Getsova, I N., and Berzinya, A. E. Analogues of pyrimidine nucleosides in chemotherapy of cancer. First All-Union Conference on Chemotherapy of Malignant Tumors, Riga, USSR, 7-11 October 1968, p 111.
2. Friedman, M. A., and Ignoffo, R. J. A review of the United States clinical experience of the fluoropyrimidine, Ftorafur (NSC-148958). Cancer Treat. Rev., 7: 205-213, 1980.
3. Byfield, J. E., Hornbeck, C. L., Frankel, S. S., Sharp, T. R., and Griffiths, J. C. Relevance of the pharmacology of oral tegafur to its use as a 5-FU prodrug. Cancer Treat. Rep., 69: 645-652, 1985.
4. Fujii, S., Kitano, S., Ikenaka, K., and Shirasaka, T. Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2′-tetrahydrofuranyl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann, 70: 209-214, 1979.
5. Yamamoto, J., Toide, K., Haruno, A., Yoshimura, Y . and Unemi, N. General pharmacological properties of UFT, a new type of anti-cancer agent consisting of 1(2-tetrahydrofuranyl)-5-fluorouracil (FT) and uracil. Drug Res., 31: 1268-1278, 1981.
6. Lokich, J., Ahlgren, J D., Gullo, J. J., Philips, J. A., and Fryer, J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J. Clin. Oncol., 7: 425-432, 1989.
7. Leichman, C. G., Leichman, L., Spears, C P., Rosen, P. J., Jeffers, S., and Groshen, S. Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a Phase II study in patients with disseminated colorectal cancer. J. Natl. Cancer Inst., 85: 41-44, 1993.
8. Ota, K., Taguchi, T., and Kimura, K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother. Pharmacol., 22: 333-338, 1988.
9. Harris, B E., Song, R., Song, S-J., and Diasio, R B. Relationship between dihydropyrimidine dehydrogenase activity and 5-fluorouracil levels with evidence of circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil. Cancer Res., 50: 197-201, 1990.
10. Muggia, F M. Managing breast cancer in an outpatient setting. Breast Cancer Res. Treat., 21: 27-34, 1992.
11. Oken, M. M., Davis, T. E., Creech, R. H., McFadden, E. T., Tormey, D. C., Carbone, P. P., and Horten, J. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol., 5, 649-655, 1982.
12. Wu, A. T., Au, J. L., and Sadee, W. Hydroxylated metabolites of R,S-1-(tetrahydro-2-furanyl) 5-fluorouracil (Ftorafur) in rats and rabbits. Cancer Res . 38: 210-214, 1978.
13. Aubert, C , Sommadossi J. P., Cassolo, P.,. Cano, J. P., and Rigault, J. P. Quantitative analysis of 5-fluorouracil and 5,6-dihydrofluorouracil in plasma by gas chromatography/mass spectiometry. Biomed. Mass Spectrum 9: 336-339, 1982.
14. Creaven, P. J , Rustum, Y. M., Petrelli, N. J., and Gorbunova, V. A. Clinical studies of the modulation of Ftorafur. In: Y. M. Rustum (ed.), Novel Approaches to Selective Treatments of Human Solid Tumors: Laboratory and Clinical Correlation, pp. 253-262. New York: Raven Press, NY 1993
15. Milano, G. 5-Fluorouracil infusional schedules J. Infusion Chemother., 2: 160-163, 1992
16. Au, J. L., Rustum, Y. M., Ledesma, E. J., Mittleman, A., and Creaven, P. J. Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in the treatment of colorectal carcinoma. Cancer Res , 42: 2930-2937, 1982
17. Milano, G., Roman, P., Khater, R., Frenay, M., Renee, N., and Namer, M Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int. J. Cancer. 41: 537-541, 1988.
18. Van Groeningen, C. J., Pinedo, H. M., Heddes, J., Kok, R. M., de long, A. P., Wattel, E., Peters, G J., and Lankelma, J. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res., 48: 6956-6961, 1988.
19. Grem, J. L., McAtee, N., Murphy, R. F., Balis, F. M., Steinberg, S M., Hamilton, J. M , Sorensen, J. M., Sartor, O., Kramer, B. S., and Goldstein, L J. A pilot study of interferon α-2a in combination with 5-fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J. Clin. Oncol., 9: 1811-1820, 1991.
20. Yoshida, T., Araki, E., Iigo, M., Fujii, T., Yoshino, M., Shimada, Y., Saito, D , Tajiri, H., Yamaguchi, H., and Yoshida, S. Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonie cancer. Cancer Chemother. Pharmacol , 26: 352-354, 1990.
21. Trump, D. L., Egorin, M. J., Forrest, A , Willson, J. K., Remick, S., and Tutsch, K. D. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72 h continuous infusion with and without dipyridamole. J. Clin. Oncol., 9: 2027-2035, 1991.
22. Aschele, C., Sobrero, A., Faderan, M. A., and Bertino, J. R. Novel mechanisms(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res., 52: 1855-1864, 1992.
23. Saltz, L. B., Leichman, C. G., Young, C. W., Muggia, F. M., Conti, J. A., Spiess, T., Jeffers, S., and Leichman, L. P. A fixed ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. Cancer (Phila.), 75: 782-785, 1995.
24. Pazdur, R., Lassere, Y., Rhodes, V., Ajani, J. A., Sugarman, S. M., Patt, Y. Z., Jones, D. V., Markowitz, A. B., Abbruzzese, J. L., Bready, B., et al Phase II trial of uracil and tegafur plus oral leucovorin. an effective oral regimen in the treatment of metastatic colorectal carcinoma. J. Clin. Oncol., 12: 2296-2300, 1994.